Using an orthotopic GL261 mouse high-grade glioma model, the authors nicely demonstrated that tumor-derived, but not host-derived, Gal-1 inhibition significantly prolonged the survival of glioma-bearing mice after a dendritic cell (DC)-based immunotherapy. The gene discussed is LGALS1; the disease is central nervous system cancer.